SecBot SecBot
6-K ·Filed Jul 13, 2026

GSK

GSK plc
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001654954-26-006614
Notable filing: 6-K
Actionable Insight ▲ Bullish

Positive AZUR-1 data de-risks a new indication for Jemperli and supports accelerated regulatory filings. Traders should watch for FDA acceptance of a supplemental BLA and potential approval timeline (likely 2027). The data also strengthens GSK's immuno-oncology positioning. Monitor for detailed results at a future scientific congress.

DirectionBullish
Confidencehigh
Horizonmonths

Drug in focus

GSK drug pipeline →

Jemperli

● Neutral Named in this 6-K
Impact
Phase
Approved (Phase 3 / registrational Phase 2 for additional indications)
Time to market
Already marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.
Next catalyst
None dated

What to watchWatch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.29
T+0 close · Jul 13, 2026 · via day close
Latest settled
−10.88%
T+60 · $46.60
Vs SPY
−14.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $52.29entry
  2. T+1 · 4mo ago −1.99%α −2.34% · $51.25
  3. T+5 · 4mo ago −1.01%α −0.23% · $51.76
  4. T+20 · 3mo ago −0.25%α −3.43% · $52.16
  5. T+60 · 6w ago −10.88%α −14.88% · $46.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer. The trial met its primary objective, showing a sustained clinical complete response rate at 12 months (cCR12), supporting the potential to eliminate or delay chemotherapy, radiation, and surgery. GSK plans to share data with global regulators, including accelerated review in the US, where Jemperli already has Breakthrough Therapy and Fast Track designations.

Key Facts

  • AZUR-1 phase II trial (n=154) met primary endpoint: sustained clinical complete response at 12 months (cCR12) in dMMR/MSI-H locally advanced rectal cancer
  • Results support potential for Jemperli to become first immunotherapy to eliminate need for chemotherapy, radiation, and surgery in some patients
  • Data to be shared with health authorities for regulatory review, including accelerated review in the US
  • Jemperli already has Breakthrough Therapy and Fast Track designations from FDA in this setting
  • Safety profile consistent with known profile across solid tumors
  • Jemperli is not currently approved anywhere for rectal cancer

Financial Impact

Expands Jemperli's addressable market into an estimated 36,500-73,000 annual dMMR/MSI-H rectal cancer patients globally; revenue contribution depends on approval and pricing, but adds to GSK's oncology pipeline value

revenuepipeline value

Risk Factors

  • Regulatory approval not guaranteed; FDA may require additional confirmatory data from a randomized trial
  • Competition from other PD-1 inhibitors (e.g., Keytruda, Opdivo) already approved in dMMR/MSI-H solid tumors
  • Single-arm phase II design may limit regulatory acceptance outside the US
  • Commercial uptake depends on pricing, reimbursement, and physician adoption of immunotherapy-only approach

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006614
Document: 0001654954-26-006614-index-headers.html0001654954-26-006614
Document: 0001654954-26-006614-index.html0001654954-26-006614
Document: 0001654954-26-006614.txt0001654954-26-006614

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026